
John Lepore, CEO & President - ProFound Therapeutics, on Proteome, AI, & Bold First-in-Class Drugs
Synopsis: This episode is proudly sponsored by Quartzy. In this far-reaching conversation, Rahul Chaturvedi speaks with John Lepore, CEO & President of ProFound Therapeutics and CEO-Partner at Flag...
3 Joulu 202535min

Jason Kelly - Ginkgo Bioworks CEO and Co-Founder on Automation, AI Data & Biotech’s Reset
Synopsis: This episode is proudly sponsored by Quartzy. Biotech is undergoing a scientific redesign, and Jason Kelly reveals to host Alok Tayi how automation, AI-ready datasets, and modular lab tec...
25 Marras 202539min

Arun Swaminathan: Coya CEO on Neuroinflammation, BD Strategy & Patient-Driven Biotech
Synopsis: In a conversation rich with strategic insight, Coya Therapeutics CEO Arun Swaminathan unpacks the intersections of scientific innovation, business development discipline, and capital-effic...
20 Marras 202537min

How Nimbus CEO Abbas Kazimi Builds Resilient Pipelines Through Culture, Rigor & Smart Bets
Synopsis: Nimbus Therapeutics CEO Abbas Kazimi walks Alok Tayi through the company’s evolving pipeline and playbook for choosing the right risks in a noisy biotech environment. From Werner helicase ...
13 Marras 202542min

Foresite Capital’s Jim Tananbaum on Biotech Cycles, AI Breakthroughs & Long-Term Value
Synopsis: Jim Tananbaum, Founder & CEO of Foresite Capital, joins Rahul Chaturvedi to dissect the patterns driving biotech innovation, the role of macroeconomic cycles in venture performance, and ho...
5 Marras 202523min

Geoffrey Duyk, Grove Biopharma CEO, on Polymer Breakthroughs, Intractable Targets & Biotech's Future
Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today’s biotech macro headwinds and building c...
23 Loka 202541min

Syndax CEO Michael Metzger on Bold Leadership, Dual Drug Launches & Redefining Cancer Care
Synopsis: Few biotechs can pull off what Syndax Pharmaceuticals has achieved — two first-in-class oncology drug launches, built entirely through strategic in-licensing and disciplined execution. In...
8 Loka 202527min

Co-creating Breakthroughs in R&D: Paul Biondi (Flagship) & Uli Stilz (Novo Nordisk)
Synopsis: When biotech meets bold partnerships, new models of innovation emerge. In this episode of the Biotech 2050 Podcast, host Rahul Chaturvedi welcomes Paul Biondi, Managing Partner at Flagship...
30 Syys 202539min
















